ArticlePathology research international2012
Genetic and epigenetic events generate multiple pathways in colorectal cancer progression.
Article in Pathology research international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Fecal DNA methylation markers for detecting stages of colorectal cancer and its precursors: a systematic review.Clinical epigenetics · 2020Pooled it
- Association between XRCC3 Thr241Met polymorphism and colorectal cancer risk.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Pooled it
- The Landscape of Genomic and Socioeconomic Variables in Patients with Colorectal Cancer Based on Genetic Ancestry.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances.Molecular biomedicine · 2026Review
- Estrogen-Induced Hypermethylation Silencing ofCells · 2026Article
- Colorectal clear cell carcinoma: a literature review.Journal of medical case reports · 2025Review
- Does side matter? Deciphering mechanisms that underpin side-dependent pathogenesis and therapy response in colorectal cancer.Molecular cancer · 2025Review
- Recent Insights into Nanotechnology in Colorectal Cancer.Applied biochemistry and biotechnology · 2024Review
- Article
- Age-Based Comparative Analysis of Colorectal Cancer Colonoscopy Screening Findings.Medicina (Kaunas, Lithuania) · 2023Article
- Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives.Pharmaceutics · 2023Review
- Molecular pathology of colorectal cancer: The Saudi situation in perspective.Saudi medical journal · 2023Review
- Specific Targeting and Labeling of Colonic Polyps inCurrent issues in molecular biology · 2023Article
- Review
- Epigenetic Alteration in Colorectal Cancer: A Biomarker for Diagnostic and Therapeutic Application.Global medical genetics · 2022Review
- Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials.Pharmaceutics · 2022Review
- MicroRNA-656-3p inhibits colorectal cancer cell migration, invasion, and chemo-resistance by targeting sphingosine-1-phosphate phosphatase 1.Bioengineered · 2022Article
- Genetic and epigenetic dependencies in colorectal cancer development.Gastroenterology report · 2022Review
- Evaluating the Microsatellite Instability of Colorectal Cancer Based on Multimodal Deep Learning Integrating Histopathological and Molecular Data.Frontiers in oncology · 2022Article
- Therapeutic Targets of KRAS in Colorectal Cancer.Cancers · 2021Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the most common causes of death, despite decades of research. Initially considered as a disease due to genetic mutations, it is now viewed as a complex malignancy because of the involvement of epigenetic abnormalities. A functional equivalence between genetic and epigenetic mechanisms has been suggested in CRC initiation and progression. A hallmark of CRC is its pathogenetic heterogeneity attained through at least three distinct pathways: a traditional (adenoma-carcinoma sequence), an alternative, and more recently the so-called serrated pathway. While the alternative pathway is more heterogeneous and less characterized, the traditional and serrated pathways appear to be more homogeneous and clearly distinct. One unsolved question in colon cancer biology concerns the cells of origin and from which crypt compartment the different pathways originate. Based on molecular and pathological evidences, we propose that the traditional and serrated pathways originate from different crypt compartments explaining their genetic/epigenetic and clinicopathological differences. In this paper, we will discuss the current knowledge of CRC pathogenesis and, specifically, summarize the role of genetic/epigenetic changes in the origin and progression of the multiple CRC pathways. Elucidation of the link between the molecular and clinico-pathological aspects of CRC would improve our understanding of its etiology and impact both prevention and treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.